Biogen pulls out of Jefferies Healthcare Conference citing COVID concerns
Florence and Joseph McGinn/iStock via Getty Images


Biogen (NASDAQ:BIIB) announced on Wednesday that the company would withdraw from the Jefferies Healthcare Conference in New York due to concerns related to COVID.
The companyâs Chief Financial Officer, Michael McDonnell, and Interim Head of R&D Priya Singhal were expected to take part on Thursday at the ongoing event.

The decision to withdraw from the investor conference comes exactly a day after the company completed its first anniversary of FDA approval of Alzheimerâs medication Aduhelm.
The anti-amyloid therapy became the first U.S.-cleared drug for the memory-robbing disease in nearly two decades when the FDA approved it under controversial circumstances in June 2021.

However, Biogen (BIIB) has struggled to increase its sales amid pushback from payors. In 1Q 2022, Aduhelm generated only $2.6M in sales for the company compared to $1M in the preceding quarter.